Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.

Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.